EyePoint Pharmaceuticals (EYPT - Free Report) reported $14.03 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 33.2%. EPS of -$0.33 for the same period compares to -$0.61 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $8.71 million, representing a surprise of +61.00%. The company delivered an EPS surprise of +45.00%, with the consensus EPS estimate being -$0.60.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how EyePoint Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Royalty income: $0.25 million versus $0.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -47.3% change.
- Revenues- Product sales, net: $0.75 million versus $0.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -92.4% change.
- Revenues- License and collaboration agreements: $13.03 million versus $7.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6350% change.
View all Key Company Metrics for EyePoint Pharmaceuticals here>>>Shares of EyePoint Pharmaceuticals have returned -12.4% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
EyePoint Pharmaceuticals (EYPT - Free Report) reported $14.03 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 33.2%. EPS of -$0.33 for the same period compares to -$0.61 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $8.71 million, representing a surprise of +61.00%. The company delivered an EPS surprise of +45.00%, with the consensus EPS estimate being -$0.60.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how EyePoint Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Royalty income: $0.25 million versus $0.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -47.3% change.
- Revenues- Product sales, net: $0.75 million versus $0.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -92.4% change.
- Revenues- License and collaboration agreements: $13.03 million versus $7.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6350% change.
View all Key Company Metrics for EyePoint Pharmaceuticals here>>>Shares of EyePoint Pharmaceuticals have returned -12.4% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on EYPT - FREE